Shire PLC (LON:SHP)‘s stock had its “outperform” rating reissued by equities researchers at BNP Paribas in a research note issued on Tuesday, StockTargetPrices.com reports. They presently have a GBX 5,900 ($74.15) target price on the biopharmaceutical company’s stock. BNP Paribas’ price objective would suggest a potential upside of 24.96% from the stock’s current price.
A number of other research firms also recently weighed in on SHP. Societe Generale reduced their target price on shares of Shire PLC from GBX 6,500 ($81.69) to GBX 6,200 ($77.92) and set a “buy” rating on the stock in a research report on Monday, March 6th. Barclays PLC began coverage on shares of Shire PLC in a research report on Wednesday, March 8th. They issued an “overweight” rating and a GBX 6,500 ($81.69) target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating on shares of Shire PLC in a research report on Monday, March 13th. Liberum Capital reaffirmed a “buy” rating and issued a GBX 5,500 ($69.12) target price on shares of Shire PLC in a research report on Thursday, March 9th. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of Shire PLC in a research report on Tuesday, February 28th. One analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of GBX 6,115.60 ($76.86).
Shares of Shire PLC (LON:SHP) opened at 4721.50 on Tuesday. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The stock’s market cap is GBX 42.62 billion. The company’s 50-day moving average is GBX 4,777.29 and its 200-day moving average is GBX 4,763.28.
The business also recently announced a dividend, which will be paid on Tuesday, April 25th. Shareholders of record on Thursday, March 9th will be paid a dividend of GBX 20.64 ($0.26) per share. The ex-dividend date is Thursday, March 9th. This represents a yield of 0.43%. This is a boost from Shire PLC’s previous dividend of $3.51.
TRADEMARK VIOLATION NOTICE: “Shire PLC’s (SHP) Outperform Rating Reaffirmed at BNP Paribas” was published by Mideast Time and is owned by of Mideast Time. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.mideasttime.com/shire-plcs-shp-outperform-rating-reaffirmed-at-bnp-paribas/1589703.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.